Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy
- Authors: Teruhiko Fujii, Keisuke Miwa, Tomoyuki Ushijima, Mototsugu Matsunaga, Masaru Fukahori, Kotaro Yuge, Uhi Toh, Nobutaka Iwakuma, Ryuji Takahashi, Hiroki Takahashi, Miki Takenaka, Mai Mishima, Yoshito Akagi, Masayoshi Kage, Shino Nakagawa, Maki Tanaka16
-
View Affiliations Hide Affiliations16 Multidisciplinary Cancer Treatment Center, Kurume University, 67 Asahi machi Kurume, 830-0011, Japan
- Source: Frontiers in Anti-Cancer Drug Discovery: Volume 4 , pp 157-228
- Publication Date: September 2014
- Language: English
Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781608059225/chapter-4-1.gif
The development of chemotherapy or endocrine therapy has improved survival in patients of breast cancer. At the same time, molecularly-targeted therapy is also an important strategy. Molecularly-targeted therapeutic strategies is an effective for breast cancer, and clinical studies have shown its potential molecular targets which include human epidermal growth factor receptor (HER), mammalian target of rapamycin (mTOR), and vascular endothelial growth factor (VEGF). However, therapy for recurrence or metastatic patients is still palliative, and the possibility of inducing complete cure for breast cancer remains remote. For this reason, many new drugs and therapeutic strategies have been investigated. Here, we reviewed the up-to-date basic and clinical developments in molecularly-targeted therapy for breast cancer, focusing on HER, mTOR, and VEGF.
-
From This Site
/content/books/9781608059225.chapter-4dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
